Avery Therapeutics

Jordan Lancaster, Ph.D., CEO
Tucson, AZ
Avery Therapeutics is a preclinical-stage company developing advanced therapies for patients suffering from cardiovascular diseases. Avery’s lead candidate is an allogeneic tissue engineered cardiac graft, MyCardia™ in development for treatment of chronic heart failure. Using Avery’s proprietary manufacturing process, MyCardia can be manufactured at scale, cryopreserved, and shipped ready to use. Avery is leveraging its proprietary tissue platform to pursue other cardiovascular indications.

By using this website you agree to accept our Privacy Policy and Terms & Conditions